High CD73 expression was associated with a worse outcome in RAS‐MAPKi‐treated patients with colorectal cancer (CRC), indicating that combined anti‐CD73 and MAPKi treatment could be beneficial for patients with CRC resistant to MAPKi therapy. This evidence concerns the gene NT5E and colorectal carcinoma.